IRIS
PAOLICELLI, DAMIANO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.575
EU - Europa 1.051
AS - Asia 536
Continente sconosciuto - Info sul continente non disponibili 7
OC - Oceania 2
SA - Sud America 2
Totale 7.173
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.569
CN - Cina 421
SE - Svezia 374
IT - Italia 236
UA - Ucraina 98
FI - Finlandia 94
GB - Regno Unito 81
DE - Germania 75
SG - Singapore 64
FR - Francia 31
BE - Belgio 24
VN - Vietnam 21
IN - India 12
CZ - Repubblica Ceca 7
SA - Arabia Saudita 6
CA - Canada 5
IR - Iran 5
EU - Europa 4
HK - Hong Kong 4
IE - Irlanda 4
NL - Olanda 4
RU - Federazione Russa 4
BG - Bulgaria 3
PT - Portogallo 3
A1 - Anonimo 2
AU - Australia 2
ES - Italia 2
GR - Grecia 2
RO - Romania 2
A2 - ???statistics.table.value.countryCode.A2??? 1
BD - Bangladesh 1
BR - Brasile 1
CH - Svizzera 1
CL - Cile 1
DK - Danimarca 1
HR - Croazia 1
IS - Islanda 1
JP - Giappone 1
KZ - Kazakistan 1
LT - Lituania 1
MK - Macedonia 1
PA - Panama 1
PL - Polonia 1
Totale 7.173
Salva come PNG Salva come JPEG
Città #
Fairfield 893
Woodbridge 603
Chandler 546
Houston 415
Ashburn 402
Seattle 393
Cambridge 311
Wilmington 299
Nyköping 298
Ann Arbor 224
Jacksonville 224
Lawrence 119
Roxbury 114
Beijing 102
Nanjing 94
Bari 80
Des Moines 74
Boardman 71
Princeton 68
New York 65
Inglewood 49
San Diego 38
Brooklyn 37
Singapore 37
Nanchang 25
Brussels 24
Shenyang 24
Dong Ket 20
Norwalk 20
Los Angeles 18
Tianjin 18
Hebei 17
Jiaxing 17
London 17
Guangzhou 16
Paris 15
Bisceglie 13
Wuhan 12
Helsinki 11
Marseille 10
Mottola 10
Munich 10
Pune 10
Redwood City 9
Brno 7
Changsha 7
Dearborn 7
Shanghai 7
Jinan 6
Milan 6
Rome 6
Taranto 6
Washington 6
Catania 5
Hefei 5
Jeddah 5
Monmouth Junction 5
San Mateo 5
Augusta 4
Dublin 4
Grottaglie 4
Hanover 4
Hong Kong 4
Jinhua 4
Kilburn 4
Ningbo 4
Senigallia 4
Ardabil 3
Lviv 3
San Francisco 3
Trani 3
Villacidro 3
Wuxi 3
Yiwu 3
Zhengzhou 3
Amsterdam 2
Bolsena 2
Chicago 2
Dalian 2
Edmonton 2
Florence 2
Grafing 2
Hangzhou 2
Hounslow 2
Imbersago 2
Indiana 2
Islington 2
Jesi 2
Kansas City 2
New Bedfont 2
Nutley 2
Palermo 2
Phoenix 2
Redmond 2
Shenzhen 2
Taizhou 2
Toronto 2
West Jordan 2
Albinea 1
Athens 1
Totale 6.063
Salva come PNG Salva come JPEG
Nome #
Prognostic indicators in pediatric clinically isolated syndrome 131
Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis 128
Long-term cardiac safety and tolerability of fingolimod in multiple sclerosis: A postmarketing study 125
The Cost of Patients With Relapsing-Remitting Multiple Sclerosis Who Develop Neutralizing Antibodies While Treated With Interferon Beta 118
null 109
Adhesion molecules and matrix metalloproteinases in Multiple Sclerosis: effects induced by Interferon-beta 106
A rare association between multiple sclerosis and Charcot-Marie-Tooth type 1B 106
The cost of relapsing-remitting multiple sclerosis patients who develop neutralizing antibodies during interferon beta therapy 105
Gender differences in safety issues during Fingolimod therapy: Evidence from a real-life Relapsing Multiple Sclerosis cohort 105
Age-related changes of serum N-acetyl-aspartate in healthy controls. 102
Lymphocyte subsets as biomarkers of therapeutic response in Fingolimod treated Relapsing Multiple Sclerosis patients 101
Impact of natalizumab on cognitive performances and fatigue in relapsing multiple sclerosis: a prospective, open-label, two years observational study. 95
Exploratory analysis of predictors of patient adherence to subcutaneous interferon beta-1a in multiple sclerosis: TRACER study 93
Retrospectively acquired cohort study to evaluate the long-term impact of two different treatment strategies on disability outcomes in patients with relapsing multiple sclerosis (RE.LO.DI.MS): data from the Italian MS Register 93
Review of interferon beta-1b in the treatment of early and relapsing multiple sclerosis. 91
Cerebrospinal fluid neurofilament light levels mark grey matter volume in clinically isolated syndrome suggestive of multiple sclerosis 91
Lymphocyte count and body mass index as biomarkers of early treatment response in a multiple sclerosis dimethyl fumarate-treated cohort 90
Mitoxantrone prior to interferon beta-1b in aggressive relapsing multiple sclerosis: a 3-year randomised trial. 89
"Better explanations" in multiple sclerosis diagnostic workup: A 3-year longitudinal study 88
Sativex in resistant multiple sclerosis spasticity: Discontinuation study in a large population of Italian patients (SA.FE. study) 88
Associations between cognitive impairment at onset and disability accrual in young people with multiple sclerosis 88
Age-related disability in multiple sclerosis 87
Long-Term Data of Efficacy, Safety, and Tolerability in a Real-Life Setting of THC/CBD Oromucosal Spray-Treated Multiple Sclerosis Patients 86
The frequency of CSF oligoclonal banding in multiple sclerosis increases with latitude. 85
Early prediction of the long term evolution of multiple sclerosis: the Bayesian Risk Estimate for Multiple Sclerosis (BREMS) score. 84
RELATIONSHIP OF COGNITIVE PERFORMANCES AND EMPLOYMENT STATUS IN PEOPLE WITH RELAPSING MULTIPLE SCLEROSIS 84
Predictors of long-term disability accrual in relapse-onset multiple sclerosis 82
Natural history of multiple sclerosis: have available therapies impacted long-term prognosis? 79
BLOOD MMP-9 AND SICAM-1 AS MARKERS OF RIFN-B TREATMENT EFFICACY IN RELAPSING-REMITTING MS 78
Predictors of disability worsening in clinically isolated syndrome 77
Epidural analgesia and cesarean delivery in multiple sclerosis post-partum relapses: the Italian cohort study. 74
DMTs and Covid-19 severity in MS: a pooled analysis from Italy and France 74
null 73
Atypical forms of Multiple Sclerosis or different phases of a same disease? 72
null 71
A multicenter, observational, prospective study of self- and parent-reported quality of life in adolescent multiple sclerosis patients self-administering interferon-β1a using RebiSmart™-the FUTURE study. 71
Patient expression of emotions and neurologist responses in first multiple sclerosis consultations 71
Postmarketing evidence of disease-modifying drugs in multiple sclerosis 70
The role of neutralizing antibodies to interferon-β as a biomarker of persistent MRI activity in multiple sclerosis: a 7-year observational study 70
null 68
null 68
Analisi longitudinale dei livelli sierici di ICAM-1 solubile e dei subsets di linfociti T in pazienti con Sclerosi Multipla a decorso remittente in trattamento con IFNb-1b 67
Low serum urate levels are associated to female gender in multiple sclerosis patients. 67
null 67
null 65
Breastfeeding is not related to postpartum relapses in multiple sclerosis. 65
null 64
null 62
The transition from relapsing-remitting MS to irreversible disability: clinical evaluation. 61
null 60
CHANGES OF SERUM ICAM-1 AND MMP-9 INDUCED BY RIFNB-1B TREATMENT IN RELAPSING-REMITTING MS 59
PBMC of Multiple Sclerosis Patients Show Deregulation of OPA1 Processing Associated with Increased ROS and PHB2 Protein Levels 59
null 58
Variations of the perforin gene in patients with multiple sclerosis. 58
null 58
Lesion load may predict long-term cognitive dysfunction in multiple sclerosis patients 57
Guidelines on the clinical use for the detection of neutralizing antibodies (NAbs) to IFN beta in multiple sclerosis therapy: report from the Italian Multiple Sclerosis Study group. 57
null 55
null 55
Long-term comparative analysis of no evidence of disease activity (NEDA-3) status between multiple sclerosis patients treated with natalizumab and fingolimod for up to 4 years 55
Interferon beta in relapsing-remitting multiple sclerosis: an independent postmarketing study in southern Italy 53
null 53
CHANGES OF SERUM SOLUBLE ICAM-1 AND MATRIX METALLOPROTEINASE-9 DURING INTERFERON BETA-1B TREATMENT IN RR MS 52
null 52
Geographical variations in sex ratio trends over time in multiple sclerosis. 51
null 51
null 50
Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: I: Fetal risks 50
null 50
The Italian Multiple Sclerosis Database Network (MSDN): the risk of worsening according to IFNbeta exposure in multiple sclerosis. 50
RIFNB DOWNREGULATES TNFA-INDUCED ICAM-1 EXPRESSION ON BRAIN MICROVASCULAR ENDOTHELIAL CELLS (BEMC) AND INCREASES SERUM SOLUBLE ICAM-1 (SICAM-1) IN RR MS 49
Durvalumab and multiple sclerosis: a causal link or simple unmasking? 48
Long-term disability trajectories in relapsing multiple sclerosis patients treated with early intensive or escalation treatment strategies 48
Pregnancy and fetal outcomes after Glatiramer Acetate exposure in patients with multiple sclerosis: a prospective observational multicentric study 47
Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: II: Maternal risks 47
Seroconversion and indolent course of COVID-19 in patients with multiple sclerosis treated with fingolimod and teriflunomide 45
The differential diagnosis of multiple sclerosis: classification and clinical features of relapsing and progressive neurological syndromes. 45
The IFN beta treatment of multiple sclerosis (MS) in clinical practice: the experience at the MS Center of Bari, Italy 44
Immunomodulatory therapies delay disease progression in multiple sclerosis. 44
null 44
Soluble Intercellular Adhesion Molecule-1 in serum and cerebrospinal fluid of demyelinating disease of the central and peripheral nervous system 43
Modificazioni dei livelli sierici di ICAM-1 solubile (sICAM.1), e Gelatinasi A e B e sottopopolazioni T-linfocitarie di sangue periferico indotte dal trattamento con interferone-beta-1b (IFN-BETA-1B) in pazienti con Sclerosi Multipla (SM) Relapsing-Remitting (RR): Relazione con la produzione di anticorpi neutralizzanti anti-interferone (NABs) 43
Transition to secondary progression in relapsing-onset multiple sclerosis: Definitions and risk factors 43
ADHESION MOLECULES AND MATRIX METALLOPROTEINASES IN MS: EFFECTS INDUCED BY INTERFERON BETA 42
IFNB-1B TREATMENT EFFECTS ON SOLUBLE INTERCELLULAR ADHESION MOLECULE-1 SERUM LEVELS AND T-CELL SUBSETS IN RELAPSING-REMITTING MULTIPLE SCLEROSIS PATIENTS. 12TH CONGRESS OF THE EUROPEAN COMMITTE FOR TREATMENT AND RESEARCH IN MULTIPLE SCLEROSIS (ECTRIMS) 40
Defining the course of tumefactive multiple sclerosis: a large retrospective multicentre study 39
COVID-19 Severity in Multiple Sclerosis: Putting Data Into Context 39
Cost-Effectiveness Analysis of Cannabinoid Oromucosal Spray Use for the Management of Spasticity in Subjects with Multiple Sclerosis 37
Harmonization of real-world studies in multiple sclerosis: Retrospective analysis from the rirems group 37
Risk of multiple sclerosis relapses when switching from fingolimod to cell-depleting agents: the role of washout duration 37
Neuromyelitis optica spectrum disorders associated with systemic sclerosis: a case report and literature review 36
PML risk is the main factor driving the choice of discontinuing natalizumab in a large multiple sclerosis population: results from an Italian multicenter retrospective study 35
VALUTAZIONE POST-MARKETING DI SICUREZZA DELL' INTERFERONE-BETA (IFN-BETA) IN PAZIENTI CON SCLEROSI MULTIPLA (SM) RELAPSING-REMITTING (RR) NELL' ITALIA MERIDIONALE. RICERCA SCIENTIFICA DELLE 34
Changes of serum sICAM-1 and MMP-9 induced by rIFN beta-1b treatment in relapsing-remitting MS 34
Effect of cladribine on neuronal apoptosis: New insight of in vitro study in multiple sclerosis therapy 32
Magnetoencephalography and high‐density electroencephalography study of acoustic event related potentials in early stage of multiple sclerosis: A pilot study on cognitive impairment and fatigue 32
EFFETTI ANTINFIAMMATORI DELL’ INTERFERONE BETA-1B RICOMBINANTE NELLA SCLEROSI MULTIPLA: STUDIO LONGITUDINALE DEI LIVELLI SIERICI DELLA FORMA SOLUBILE DI INTERCELLULAR ADHESION MOLECULE-1 (SICAM-1) E DEI SUBSETS LINFOCITARI 31
Longitudinal Evaluation of Serum MOG-IgG and AQP4-IgG Antibodies in NMOSD by a Semiquantitative Ratiometric Method 31
SERUM AND CSF CHANGES OF MATRIX METALLOPROTEINASES (MMPS) AND THEIR TISSUE INHIBITORS (TIMPS) DURING DISEASE COURSE AND INTERFERON BETA TREATMENT IN MULTIPLE SCLEROSIS (MS) 30
Soluble intercellular adhesion molecule-I (sICAM-I) in serum and cerebrospinal fluid of demyelinating diseases of the central and peripheral nervous system 30
Totale 6.513
Salva come PNG Salva come JPEG
Categoria #
all - tutte 34.904
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 34.904
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.623 0 96 51 161 187 108 194 200 231 126 224 45
2020/20211.390 104 80 111 113 163 100 132 101 107 166 125 88
2021/2022938 57 109 16 33 44 88 43 46 86 59 175 182
2022/20231.438 229 184 85 138 170 167 17 169 211 5 27 36
2023/2024475 57 71 29 31 39 109 13 18 9 23 6 70
2024/2025165 133 32 0 0 0 0 0 0 0 0 0 0
Totale 7.502